Abionyx Pharma SA (ABNX)
Euronext
Closed
Oct 2, 2026
Day's Range
1.6152 wk Range
1.61Overview - ABNX - Abionyx Pharma SA
Key Statistics
Valuation
Enterprise Value
65.22M
P/E (Trailing)
‪-10.43‬
P/E (Forward)
‪-6.08‬
PEG Ratio
‪-6.08‬
Price / Sales (TTM)
‪18.31‬
Price / Book
‪13.35‬
EV / EBITDA
‪-12.02‬
Profitability
Profit Margin
‪-136.59%‬
Operating Margin
‪-165.02%‬
Return on Assets
‪-25.97%‬
Return on Equity
‪-92.29%‬
Ownership
Shares Outstanding
35.83M
Float
22.33M
Held by Insiders
‪29.17%‬
Held by Institutions
‪3.63%‬
Price stats
Beta
‪0.45‬
50-Day Avg
‪1.92‬
200-Day Avg
‪3.00‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Market Cap - ABNX - Abionyx Pharma SA
Peers - ABNX - Abionyx Pharma SA
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - ABNX - Abionyx Pharma SA
About
Abionyx Pharma SA is a new-generation biotechnology company focused on discovering and developing innovative therapies for patients lacking effective treatments, particularly in renal and ophthalmological diseases. It specializes in HDL (High Density Lipoprotein) therapies, leveraging advanced lipoprotein particles to…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
